💻Code of Life

Completion of the Human Genome Regulatory Map: ENCODE4 Deciphers 92 Million Enhancer-Gene Connections

Nature·July 16, 2026AI Curation
Completion of the Human Genome Regulatory Map: ENCODE4 Deciphers 92 Million Enhancer-Gene Connections
AI Summary (Beta)Beta

Background

The human genome contains approximately 20,000 protein-coding genes, but the non-coding regions that regulate their expression account for 98% of the genome. Enhancers are key regulatory elements dispersed within these non-coding regions, orchestrating the spatio-temporal regulation of target gene expression. The challenge lies in systematically identifying which enhancers regulate which genes.

Previous studies have estimated enhancer-gene connections in individual cell lines or a limited number of tissues, but a comprehensive map encompassing hundreds of cell types at the whole-genome scale has been lacking. The ENCODE (Encyclopedia of DNA Elements) project has conducted over 16,000 genomic experiments over two decades, building a catalog of gene regulatory elements. However, a systematically organized encyclopedia of functional connections between enhancers and their target genes, categorized by cell type, remained a gap.

Key Findings

The ENCODE4 consortium has completed an encyclopedia mapping over 92 million enhancer-gene regulatory interactions across more than 352 cell types and tissues. This represents a roughly seven-fold expansion compared to the 13 million reported in a 2023 preprint, enabled by the integration of an expanded registry of candidate cis-regulatory elements (cCREs) of 2.37 million and additional biosample data.

The research team developed a new predictive model called ENCODE-rE2G (ENCODE-regulatory Element to Gene). This model goes beyond the existing ABC (Activity-by-Contact) model, employing a logistic regression-based supervised learning approach that utilizes 13 features derived from DNase-seq data. A key finding is that, in addition to enhancer activity and the frequency of three-dimensional enhancer-promoter contacts, promoter class and enhancer-enhancer synergy are crucial determinants of enhancer-promoter communication.

Model validation utilized 10,411 element-gene pairs measured in CRISPR interference experiments, over 30,000 precisely mapped eQTLs, and 569 precisely mapped GWAS variants associated with causal genes. ENCODE-rE2G achieved an average recall of 78% in ChIA-PET and HiChIP contact benchmarks, surpassing the 74% of the ABC model, demonstrating superior predictive performance. A four-feature model combining promoter characteristics with the ABC score further improved the AUPRC by 0.044.

Significance and Prospects

This encyclopedia systematically links non-coding variants to target genes for 94 GWAS traits, potentially resolving a major bottleneck in the interpretation of disease-associated genetic variants. Analyses of 197 non-coding credible sets and tissue enrichment for 76 traits have already been performed.

However, limitations exist. The current map relies heavily on data from bulk tissues, and validation at single-cell resolution is still in its early stages. Furthermore, additional research is needed to capture the dynamic changes in enhancer-gene connections, i.e., the rewiring that occurs during development or in disease states. The predictive performance of the ENCODE-rE2G model also varies depending on the cell type, so improving accuracy in rare cell types remains a challenge.

Nature, Published online: 15 July 2026; doi:10.1038/s41586-026-10781-4 An encyclopedia of more than 92 million enhancer–gene regulatory interactions created as part of the ENCODE4 project provides a valuable resource for future studies of gene regulation and human genetics.

💬Why it matters:

Non-coding variants associated with disease account for more than 90% of the risk variants identified by GWAS, but it has been difficult to pinpoint which genes they affect, hindering the discovery of new drug targets. This encyclopedia directly links enhancers and target genes by cell type, providing a foundation for pharmaceutical companies to systematically trace the path from GWAS hits to new drug target genes.

For example, if an enhancer that is only active in certain immune cells is the cause of a GWAS signal for an autoimmune disease, it may be possible to design cell-type-specific therapies that target that gene. It can also be directly used to determine the pathogenicity of non-coding variants in the field of genomic diagnostics, and it is expected to provide clues to reclassify a considerable number of variants that are currently classified as variants of uncertain significance (VUS).

💬 Comments

0 comments
Please log in to comment
Loading...